GET DAILY SIGNALSOvid Therapeutics (OVID): Analyst Targets Highlight Path to $6.00
Key Takeaways
- The central stock price target used here is $6.00, the arithmetic mean of eight verified current analyst targets rounded to a clean figure.
- The latest verified price is about $2.26, meaning a move to $6.00 would require roughly 165% upside — a very large move.
- The verified analyst targets reviewed range from $5.00 to $9.00, and recent ratings are uniformly Buy or Strong Buy.
- Supporting factors include early-stage progress in the OV329 and OV4071 programs and inclusion in the S&P Biotechnology Select Industry Index.
- Key risks include a pre-revenue, clinical-stage profile, ongoing cash burn, share dilution, and binary trial outcomes.
- For more context, see Major News and Today's Price Move, plus the Forecast and Earnings pages.
- Explore Trending AI Robots to see how AI-driven strategies are monitoring names like OVID.
Analyst Price Targets and Consensus View
This review examined eight current, individually attributable analyst price targets. They range from a low of $5.00 (Wolfe Research, Oct. 15, 2026; H.C. Wainwright and UBS, both raised to $5.00 in September 2026; B. Riley, July 2026) to a high of $9.00 (Oppenheimer, raised from $7.00 in August 2026). Wedbush maintained a $7.00 target (Oct. 8, 2026), Guggenheim initiated at $7.00 (Oct. 5, 2026), and Cantor Fitzgerald initiated at $6.00 (Oct. 9, 2026).
The arithmetic mean of these eight targets is approximately $6.13, which rounds to the $6.00 central target used throughout this article. Third-party aggregators report a similar picture: a Strong Buy consensus with an average target near $6.00 and a low-to-high range of $4.00 to $9.00 across roughly 12 to 13 analysts. The tight cluster of recent initiations and upward revisions — several firms raised targets from $4.00–$5.00 to $5.00–$9.00 during 2026 — reflects growing enthusiasm around the company's psychosis and epilepsy programs rather than a single dominant view. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At roughly $2.26 per share, OVID carries a market capitalization of about $441 million and sits within a 52-week range of $1.18 to $3.11. Reaching $6.00 would require approximately 165% appreciation — a very large move that would imply roughly tripling the current valuation.
The company's path is defined less by near-term revenue than by clinical milestones. OVID remains pre-revenue at scale, with trailing twelve-month revenue near $1.6 million and a net loss of about $34 million. Its value proposition rests on the pipeline, notably OV329, a next-generation GABA-AT inhibitor in Phase 1 for drug-resistant epilepsies, and OV4071, an oral potassium-chloride cotransporter 2 (KCC2) activator in Phase 1 for psychosis associated with Parkinson's disease, Lewy body dementia, and schizophrenia. Positive early data and planned Phase 2a work underpin the bullish analyst framework.
What Could Support a Move Toward the Target
Several factors inform the optimistic analyst price targets. First, the company's balance sheet is relatively strong for a clinical-stage firm, with roughly $117 million in cash and a net cash position near $157 million, providing runway to advance trials. Second, pipeline breadth — spanning epilepsy and psychosis indications — offers multiple shots on goal. Third, analysts have explicitly cited expected revenue from Lewy body dementia psychosis and Parkinson's disease psychosis indications in raising targets after the Phase 1 initiation of OV4071. Finally, inclusion in the S&P Biotechnology Select Industry Index can attract passive and institutional flows, and a heavily shorted float (about 9.7% of shares outstanding) could amplify upside on positive catalysts.
What Could Prevent the Target From Being Reached
The risks are substantial. OVID has no approved products, and its valuation depends on clinical data that can fail or disappoint. Cash burn is significant, and the share count has risen sharply — up roughly 71% year over year — reflecting dilution that weighs on per-share value. Any clinical setback, regulatory delay, or slower-than-expected trial enrollment could compress the multiple. Additionally, the company's history includes pipeline reorganizations, and the $5.00-to-$9.00 target spread itself signals genuine uncertainty about which programs will deliver value.
Technical Levels and Market Structure
OVID trades near $2.26, below both its 50-day moving average (about $2.56) and 200-day moving average (about $2.35), suggesting short-term and longer-term momentum has been soft despite a year-to-date gain. The 52-week low of $1.18 (November 2025) marks a key psychological and technical support level, while the 52-week high of $3.11 (April 2026) represents the nearest major resistance level that would need to be cleared before any move toward the $6.00 target could begin. A sustained break above $3.11 would be a notable structural change; a drop below the mid-$2.00 zone would keep the stock well below the analyst mean.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ. For OVID, the next meaningful catalyst is the company's earnings report, currently expected around November 11, 2026, along with any commentary on cash runway and pipeline timing. Investors should also watch Phase 2a initiation and data readouts for OV329, progress on OV4071, analyst target revisions, changes in short interest, and index-related fund flows. None of these items provides a guaranteed timeline for reaching $6.00.
Using AI Daily Buy/Sell Signals for Monitoring
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track names like OVID amid daily volatility. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. I find it helpful for spotting momentum changes and managing positions in clinical-stage biotechs without relying solely on manual review.
Final Assessment
Can Ovid Therapeutics (OVID) stock reach $6.00? The target is the rounded arithmetic mean of eight current analyst price targets, which span a wide $5.00 to $9.00 range and imply roughly 165% upside from the latest price near $2.26. The bull case rests on pipeline optionality in epilepsy and psychosis, a fortified cash position, and a wave of recent analyst initiations and upgrades. The bear case rests on the company's pre-revenue status, ongoing losses, dilution, and the binary nature of clinical-stage biotech. Reaching $6.00 would require not only successful data but a sustained re-rating well beyond current technical resistance. That is a very large move, and the outcome will hinge primarily on clinical execution and the durability of the cash runway.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OVID's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for OVID moved into oversold territory on October 26, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Oscillator exited the oversold zone, 19 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.
Following a +13.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In 83 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
OVID moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OVID crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.037). P/E Ratio (-10.762) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology
Advertisement